Mark Lazarus

2.2k total citations · 1 hit paper
8 papers, 1.8k citations indexed

About

Mark Lazarus is a scholar working on Rheumatology, Radiology, Nuclear Medicine and Imaging and Immunology. According to data from OpenAlex, Mark Lazarus has authored 8 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Rheumatology, 3 papers in Radiology, Nuclear Medicine and Imaging and 3 papers in Immunology. Recurrent topics in Mark Lazarus's work include Systemic Lupus Erythematosus Research (4 papers), T-cell and B-cell Immunology (3 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). Mark Lazarus is often cited by papers focused on Systemic Lupus Erythematosus Research (4 papers), T-cell and B-cell Immunology (3 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). Mark Lazarus collaborates with scholars based in United Kingdom, United States and Sweden. Mark Lazarus's co-authors include Ian V. Hutchinson, David M. Turner, P. J. Sinnott, Denise Williams, David Sankaran, Jane Worthington, Ali H. Hajeer, Paul J. Sinnott, William Ollier and Michael R. Ehrenstein and has published in prestigious journals such as Annals of the Rheumatic Diseases, European Journal of Immunology and Lara D. Veeken.

In The Last Decade

Mark Lazarus

8 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

AN INVESTIGATION OF POLYMORPHISM IN THE INTERLEUKIN‐10 GENE PROMOTER

1997 1.5k citations David M. Turner, Denise Williams et al. European Journal of Immunogenetics profile →

Peers

Countries citing papers authored by Mark Lazarus

Since Specialization

Citations

This map shows the geographic impact of Mark Lazarus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Lazarus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Lazarus more than expected).

Fields of papers citing papers by Mark Lazarus

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Lazarus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Lazarus. The network helps show where Mark Lazarus may publish in the future.

Co-authorship network of co-authors of Mark Lazarus

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Lazarus. A scholar is included among the top collaborators of Mark Lazarus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Lazarus. Mark Lazarus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

#	Work	Indexed citations
1	Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials 2024 ·Annals of the Rheumatic Diseases ·Tina Baker, (unknown), Paul J. Newcombe, Patrick G. Gavin, Mark Lazarus, Madhu Ramaswamy, Wendy I. White, Nicola Ferrari, Daniel Muthas, Raj Tummala, Eric F. Morand, Richard Furie, Edward M Vital, Chris Chamberlain, Adam Platt, Hussein Al‐Mossawi, Philip Z. Brohawn, Eszter Csomor	32
2	OP0136 METABOLOMIC SERUM PROFILING IDENTIFIES METABOLITES LINKED TO KIDNEY DAMAGE WHICH ARE MODULATED BY ANIFROLUMAB IN A PHASE 2 TRIAL IN LUPUS NEPHRITIS 2023 ·Annals of the Rheumatic Diseases ·David Jayne, Patrick J. Gavin, Erik L. Allman, Cristina Di Poto, Xinping Tian, Sonja Hess, Madhu Ramaswamy, Mark Lazarus, Philip Z. Brohawn, Daniel Muthas, Adam Platt, Hussein Al‐Mossawi, Catharina Lindholm, (unknown)	2
3	132 Adherence to National Institute for Health and Care Excellence Guidance on Methotrexate Blood Monitoring in a Central London National Health Service Trust 2016 ·Lara D. Veeken ·Kristina E N Clark, (unknown), Mark Lazarus, (unknown), (unknown), Jane Dacre, Elena Nikiphorou	1
4	B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels 2012 ·Lara D. Veeken ·Mark Lazarus, Tabitha Turner‐Stokes, Konstantia-Maria Chavele, David Isenberg, Michael R. Ehrenstein	57
5	An association between corticosteroid use and melanoma recurrence: a case report and review of the literature 2011 ·Medical Oncology ·Mark Lazarus, Howard L. Kaufman	2
6	Abnormal CTLA‐4 function in T cells from patients with systemic lupus erythematosus 2009 ·European Journal of Immunology ·Elizabeth C. Jury, Fabian Flores‐Borja, (unknown), Mark Lazarus, David Isenberg, Claudia Mauri, Michael R. Ehrenstein	46
7	AN INVESTIGATION OF POLYMORPHISM IN THE INTERLEUKIN‐10 GENE PROMOTER breakdown → 1997 ·European Journal of Immunogenetics ·David M. Turner, Denise Williams, David Sankaran, Mark Lazarus, P. J. Sinnott, Ian V. Hutchinson	1483
8	Genetic variation in the interleukin 10 gene promoter and systemic lupus erythematosus. 1997 ·PubMed ·Mark Lazarus, Ali H. Hajeer, David M. Turner, Paul J. Sinnott, Jane Worthington, William Ollier, Ian V. Hutchinson	204

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact